Literature DB >> 3254831

Effects of long term treatment with pinacidil and nifedipine on left ventricular anatomy and function in patients with mild to moderate systemic hypertension.

F Steensgaard-Hansen1, J E Carlsen.   

Abstract

Hypertrophy of the left ventricle in hypertension is associated with an increased risk of morbidity and mortality. Thus, the prevention of and regression of left ventricular hypertrophy should be essential goals of antihypertensive treatment. Some commonly used antihypertensive drugs do not have this ability, despite achieving adequate blood pressure control. In a double-blind randomised parallel group study, we evaluated the effects of adjunctive long term therapy with either pinacidil or nifedipine on blood pressure and left ventricular function and anatomy (echocardiography) in 22 patients with a diastolic blood pressure above 95mm Hg who were already receiving bendrofluazide 5mg daily. Pinacidil reduced left ventricular mass from 326.3 +/- 126.2g to 251.2 +/- 114.6g (p less than 0.001) compared with nifedipine, which reduced ventricular mass from 293.6 +/- 35.7g to 267.3 +/- 34.7 (p = 0.04). In this respect, pinacidil was more effective than nifedipine (p = 0.013). Pinacidil improved left ventricular diastolic function, measured by the isovolumetric relaxation time, whereas nifedipine did not affect this parameter. Global systolic function was little affected by either drug. However, the end systolic wall stress was significantly reduced by both therapeutic regimens. Pinacidil may, therefore, be a potentially valuable antihypertensive drug.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3254831     DOI: 10.2165/00003495-198800367-00013

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  32 in total

1.  Cardiac hypertrophy in spontaneously hypertensive rats.

Authors:  S Sen; R C Tarazi; P A Khairallah; F M Bumpus
Journal:  Circ Res       Date:  1974-11       Impact factor: 17.367

2.  Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study.

Authors:  W B Kannel; T Gordon; W P Castelli; J R Margolis
Journal:  Ann Intern Med       Date:  1970-06       Impact factor: 25.391

3.  Hemodynamics and other determinants in development of left ventricular hypertrophy.

Authors:  E D Frohlich
Journal:  Fed Proc       Date:  1983-07

4.  Immediate central and peripheral haemodynamic effects of a new vasodilating agent Pinacidil (P1134) in hypertensive man.

Authors:  J E Carlsen; T Kardel; T Hilden; M Tangø; J Trap-Jensen
Journal:  Clin Physiol       Date:  1981-08

5.  Cardiovascular effects of verapamil in patients with essential hypertension.

Authors:  R E Schmieder; F H Messerli; G E Garavaglia; B D Nunez
Journal:  Circulation       Date:  1987-05       Impact factor: 29.690

6.  Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response.

Authors:  P Simpson
Journal:  J Clin Invest       Date:  1983-08       Impact factor: 14.808

7.  Cardiac hypertrophy and antihypertensive therapy.

Authors:  S Sen; R C Tarazi; F M Bumpus
Journal:  Cardiovasc Res       Date:  1977-09       Impact factor: 10.787

8.  In vitro studies on the mode of action of pinacidil.

Authors:  A H Weston; K M Bray; S Duty; A D McHarg; D T Newgreen; J S Southerton
Journal:  Drugs       Date:  1988       Impact factor: 9.546

9.  Cholesterol potentiates the coronary artery response to norepinephrine in anesthetized and conscious dogs.

Authors:  C Rosendorff; J I Hoffman; E D Verrier; J Rouleau; L E Boerboom
Journal:  Circ Res       Date:  1981-03       Impact factor: 17.367

10.  Regression of cardiac hypertrophy: experimental and clinical results.

Authors:  W Motz; M Klepzig; B E Strauer
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

View more
  2 in total

Review 1.  Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension.

Authors:  H A Friedel; R N Brogden
Journal:  Drugs       Date:  1990-06       Impact factor: 9.546

Review 2.  Smooth muscle K+ channel openers; their pharmacology and clinical potential.

Authors:  A H Weston
Journal:  Pflugers Arch       Date:  1989       Impact factor: 3.657

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.